Harbin Pharmaceutical Group Co., Ltd. (600664.SH)
Trading Activity and Institutional Interest (July 21‑23, 2026)
| Date | Event | Details |
|---|---|---|
| July 21, 2026 | Strong intraday rally | The stock opened at 5.98 CNY and hit the daily limit, creating a “ge‑tian” (floor‑to‑ceiling) rally. The intraday volume exceeded 36 billion CNY, the highest for the day. Institutional buyers from the Shanghai Stock Exchange and the “Hushang” (沪股通) trading desk were among the top net buyers, with net purchases of 10,126.85 million CNY and 10,342.13 million CNY respectively. |
| Sector context | The pharmaceutical sector was broadly positive, with 119 stocks hitting the daily limit on the A‑share market. Harbin Pharmaceutical was cited as one of the strongest performers alongside Hua Yin Power (600744) and Gong Jin Shares (603118). | |
| Fundamental backdrop | The company’s 2026 market cap is 15.06 billion CNY, with a price‑earnings ratio of 48.37. Its share price range over the last 52 weeks is 2.84 – 6.35 CNY. The firm’s product portfolio includes penicillin, calcium gluconate, and traditional Chinese medicines. | |
| July 22, 2026 | Net selling on the “Liu‑Hua” board | Harbin Pharmaceutical appeared on the 10‑largest net‑sell list for the day, with a net outflow of 5.95 billion CNY. The stock closed 10.0 % lower, with a turnover rate of 6.97 %. |
| July 23, 2026 | Net buying dominates the “Liu‑Hua” board | The top net‑buyer on the day was Harbin Pharmaceutical, with a net purchase of 12.11 billion CNY. This placed the stock among the 22 shares that recorded institutional net buying, outpacing the 25 shares that saw net selling. |
| Broader market movements | The day’s trading saw a significant number of stocks hitting the limit, with 47 shares exhibiting institutional activity. Harbin Pharmaceutical’s position in the top‑buyer list highlights sustained institutional confidence. |
Regulatory and Market‑Event Highlights
- Anomalous trading alerts (July 24, 2026) – An official announcement flagged “severe abnormal price fluctuations” for the stock, prompting a risk‑warning notice. The alert followed a sequence of high‑volume limit‑up days and a recent net‑buy surge.
- Innovation‑drug catalyst (July 21, 2026) – A newly approved “selective orexigenic peptide receptor agonist” received its first market launch in China. The approval, announced by the National Medical Products Administration, was expected to benefit the company’s portfolio of innovative pharmaceuticals and may have contributed to the intraday rally on July 21.
Summary
Harbin Pharmaceutical Group’s trading activity over the three‑day span demonstrates strong institutional support, highlighted by a net buy of 12.11 billion CNY on July 23, following a high‑volume “ge‑tian” rally on July 21. The firm’s market capitalization, high price‑earnings ratio, and recent regulatory developments underscore its position as a leading player within China’s pharmaceutical sector.
